Par Pharmaceutical (PRX) Receives Patent Relating to Megace ES 625 mg/5 mL Oral Suspension
Tweet Send to a Friend
Par Pharmaceutical Companies, Inc. (NYSE: PRX) announced that a new patent has been issued by the U.S. Patent and Trademark ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


